Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma

Cancer Journal (United States)

Volumn 18, Issue 5, 2012, Pages 457-462

  Khouri, Issa F ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Allogeneic; graft versus lymphoma; lymphoma; nonmyeloablative

Indexed keywords

BENDAMUSTINE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; MELPHALAN; METHOTREXATE; RITUXIMAB; TACROLIMUS;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVIEW; T CELL LYMPHOMA; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84866903964     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31826b124c     Document Type: Review

References (47)

1. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667-668.
2. Hosing C, SalibaRM, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol. 2003;14:737-744.
3. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
4. Tam CS, Bassett R, Ledesma C, et al. Mature results of the MDAnderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009;113:4144-4152.
5. Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:2240-2247.
6. Chakhachiro ZT, Saliba RM, Okoroji GJ, et al. 12-Year experience with high-dose rituximab-containing autologous stem cell transplantation for SOX11-positive mantle cell lymphoma patients in first remission: emerging lymphoma-free survival plateau after 3 years. Blood. 2011;118. Abstract 662.
7. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101:2015-2023.
8. Laport G, Bredeson CN, Tomblyn M, et al. Autologous versus reduced intensity allogeneic hematopoietic cell transplantation for patients with follicular non-Hodgkin's lymphoma (FL) beyond first complete response or first partial response. J Clin Oncol. 2008:26. Abstract 7041.
9. Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLAidentical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010;16:35-45.
10. Van Besien KW, de Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versuslymphoma effects. Bone Marrow Transplant. 1997;19:977-982.
11. Mandigers CM, Verdonck LF, Meijerink JP, et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32:1159-1163.
12. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32:28-35.
13. Thomson KJ, Morris EM, Milligon D, et al. T-cellYdepleted reducedintensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010;28:3695-3700.
14. Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111:5530-5536.
15. Khouri IF, Lee M-S, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for advanced/recurrent mantle cell lymphoma. J Clin Oncol. 2003;21:4407-4412.
16. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reducedintensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172-2176.
17. Khouri IF, Saliba RM, Erwin WD, et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results [published online ahead of print May 14, 2012]. Blood. 2012.
18. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677-2684.
19. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression- free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687-2693.
20. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104: 3535-3542.
21. Philip T, Guglielmi C, Hagenbeek A, et al. ABMTas compared with salvage chemotherapy in relapses of chemosensitive NKL. N Engl J Med. 1995;333:1540-1545.
22. Alousi AM, Saliba RM, Okoroji, GJ, et al. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol. 2008;142:786-792.
23. Bishop MR, Dean RM, Steinberg SM, et al. Correlation of pretransplant and early posttransplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Cancer. 2010;116:852-862.
24. Dean RM, Fowler DH, Wilson WH, et al. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non- Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11:593-599.
25. Lambert JR, Bomanji JB, Peggs KS, et al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood. 2010;115:2763-2768.
26. Alizadeh A, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
27. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117:2319-2331.
28. Escalon MP, Champlin RE, Saliba RM, et al. Nonmyeloablative allogeneic haematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol. 2004;22:2419-2423.
29. van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29:1342-1348.
30. Foss FM, Zinzani PL, Vose JM, et al. Peripheral t-cell lymphoma. Blood. 2011;117:6756-6767.
31. Beitinjaneh A, Saliba RM, Okoroji GJ, et al. Autologous and allogeneic stem cell transplantation for T-cell lymphoma: the M.D. Anderson Cancer Center experience. Blood. 2011;118. Abstract 4118.
32. Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and nonmyeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28:2365-2372.
33. Jacobsen ED, Kim HT, Ho VT, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non- Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011;11:1608-1613.
34. Khouri IF, Saliba RM, Korbling M, et al. Nonmyeoablative allogeneic conditioning with bendamustine in combination with fludarabine and rituximab for lymphoid malignancies: immunosuppression withoutmyelosuppression and without acute GVHD. Blood. 2011;118. Abstract 894.
35. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
36. Hsu FJ, Komarovskaya M. CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother. 2002;25: 455-468.
37. Khouri IF, Bassett R, Poindexter N, et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome [published online ahead of print March 31, 2011]. Cancer. 2011.
38. Arai S, Sahaf B, Narasimhan B, et al. Prophylactic rituximab after allogeneic transplantation decreases B cell alloimmunity with low chronic GVHD incidence [published online ahead of print May 4, 2012]. Blood. 2012.
39. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576-4583.
40. Ho VT, Kim HT, Aldridge J, et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1196-1204.
41. Brunstein CG, Cantero S, Cao Q, et al. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009;15:214-222.
42. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641-650.
43. Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cellYdepleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol. 2011;29:971-978.
44. Goldstein SC, Levine B, Smith J, et al. First report of the prophylactic administration of ex vivo co-stimulated donor lymphocyte infusion (DLI) from related and unrelated donors after reduced intensity conditioning for high risk hematologic malignancies [abstract]. Blood. 2009;112:468.
45. Kochenderfer JN, Dudley M, Maric I, et al. Dramatic regression of chronic lymphocytic leukemia in the first patient treated with donor derived genetically engineered antiYCD 19 chimeric antigen receptor expressing T cells after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:S158.
46. Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NKlymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18:1835-1838.
47. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116: 2411-2419.